Glycaemic control efficacy of switching from semaglutide to tirzepatide in subjects with type 2 diabetes

Glycaemic control efficacy of switching from semaglutide to tirzepatide in subjects with type 2 diabetes - Glycaemic control efficacy of switching from semaglutide to tirzepatide in subjects with type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000055507

Enrollment

Registered

2024-10-01

Start date

2024-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Tirzepatide is initiated at a dose of 2.5 mg once weekly, and the doses is increased by 2.5 mg every 4 weeks until the assigned dose.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Key inclusion criteria for the trial were an age of 20 years or older and type 2 diabetes that was inadeguately contorolled with semaglutide 1.0 mg.Eligible patients had a glycated hemoglobin level of 6.5 to 10.5%

Exclusion criteria

Exclusion criteria: Key exclusion criteria were type 1 diabetes;and a histoly of any of the following:nonproliferatine diabtetic retinopathy that warranted urgent treatment,proliferative diabetic reitopathy, or diabetic maculopathy.

Design outcomes

Primary

Measure	Time frame
The primary end point was the change in the glycated hemoglobin level from baseline to week 52.	—

Countries

Japan

Contacts

Public ContactSusumu Kurihara

Saitama Medical University Hospital Department of Endocrinology and Diabetes

sk3512@saitama-med.ac.jp049-276-1204

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026